patents.google.com

SG11201901991QA - Methods of detecting per cell pd-l1 expression and uses thereof - Google Patents

  • ️Mon Apr 29 2019

SG11201901991QA - Methods of detecting per cell pd-l1 expression and uses thereof - Google Patents

Methods of detecting per cell pd-l1 expression and uses thereof

Info

Publication number
SG11201901991QA
SG11201901991QA SG11201901991QA SG11201901991QA SG11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA Authority
SG
Singapore
Prior art keywords
international
methods
expression
california
per cell
Prior art date
2016-09-06
Application number
SG11201901991QA
Inventor
Bruce K Patterson
Amanda Noel Chargin
Keith Shults
Original Assignee
Incelldx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2016-09-06
Filing date
2017-09-06
Publication date
2019-04-29
2017-09-06 Application filed by Incelldx Inc filed Critical Incelldx Inc
2019-04-29 Publication of SG11201901991QA publication Critical patent/SG11201901991QA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1006Investigating individual particles for cytology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486Counting the particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532B7 molecules, e.g. CD80, CD86
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 011101111110111111 OHRE III OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/048936 Al 15 March 2018 (15.03.2018) WIP0 I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) International Patent Classification: (74) Agent: FIELD, Bret E.; 201 Redwood Shores Parkway, G01N 1/30 (2006.01) G01N 33/574 (2006.01) Suite 200, Redwood City, California 94065 (US). G01N 33/483 (2006.01) G01N 15/14 (2006.01) (81) Designated States (unless otherwise indicated, for every International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/050322 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 06 September 2017 (06.09.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/384,037 06 September 2016 (06.09.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: INCELLDX, INC. [US/US]; 1700 El Camino (84) Designated States (unless otherwise indicated, for every Real, Menlo Park, California 94027 (US). kind of regional protection available): ARIPO (BW, GH, Inventors; and GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Applicants: PATTERSON, Bruce K. [US/US]; 274 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Mosher Way, Palo Alto, California 94304 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CHARGIN, Amanda Noel [US/US]; 11 Jackson Street, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, San Jose, California 95112 (US). SHULTS, Keith TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, [US/US]; 9825 Sam Donald Road, Nolensville, Tennessee KM, ML, MR, NE, SN, TD, TG). 37135 (US). = = = Title: METHODS OF , — ..-_-, (54) DETECTING PER CELL PD-L1 EXPRESSION AND USES THEREOF , of neoplasia cells. to detect whether addition, kits that find = = C , pos(77 20 %) PD-L1 pos(0.21 %) = = = = _ = = : Methods are of the methods include cytometrically assaying a labeled cell suspension neoplastic cell that expresses PD-L1 above a predetermined threshold in practicing the subject methods are also provided. -- -- GO Aspects 1 i 0 2 10' 10• 10 5 10 7 10' APC-A FIG, 1 provided for detecting the per cell programmed 1 . Q - 10 4 10 5 1 0 5 10 7 APC-A -death ligand 1 (PD-L1) expression to quantify per cell PD-L 1 expression is present in the neoplasia sample. In _ Il .4 M tz. co ii- © (57) ,-1 a 0 use ei O [Continued on next page] WO 2018/048936 Al MIDEDIMOMMIDEFIEHVIVEHEMERMOVOIS Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of

SG11201901991QA 2016-09-06 2017-09-06 Methods of detecting per cell pd-l1 expression and uses thereof SG11201901991QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384037P 2016-09-06 2016-09-06
PCT/US2017/050322 WO2018048936A1 (en) 2016-09-06 2017-09-06 Methods of detecting per cell pd-l1 expression and uses thereof

Publications (1)

Publication Number Publication Date
SG11201901991QA true SG11201901991QA (en) 2019-04-29

Family

ID=61561676

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901991QA SG11201901991QA (en) 2016-09-06 2017-09-06 Methods of detecting per cell pd-l1 expression and uses thereof

Country Status (11)

Country Link
US (1) US10782298B2 (en)
EP (1) EP3510378A4 (en)
JP (2) JP2019535001A (en)
CN (2) CN109906367A (en)
BR (1) BR112019004470A2 (en)
CA (1) CA3036278A1 (en)
CR (1) CR20190172A (en)
IL (1) IL265175A (en)
MX (1) MX2019002578A (en)
SG (1) SG11201901991QA (en)
WO (2) WO2018048936A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019004470A2 (en) * 2016-09-06 2019-09-03 Incelldx Inc methods for detecting pd-l1 expression by cells and its uses
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
CN112740042A (en) * 2018-09-20 2021-04-30 文塔纳医疗系统公司 Based on size gating to analyze flow cytometry data
CN113330310A (en) * 2018-11-09 2021-08-31 皮埃里亚生物科学有限责任公司 Methods and compositions for determining tumor microenvironment composition
WO2020168244A1 (en) * 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
CN110142068B (en) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 Kit and method for detecting epithelial and mesenchymal mixed circulating tumor cells
CN111735955A (en) * 2020-04-20 2020-10-02 山东省肿瘤防治研究院(山东省肿瘤医院) Immunofluorescence detection method for PD-L1 expression on peripheral blood circulation tumor cells of hepatocellular carcinoma patient
CA3211402A1 (en) * 2021-03-10 2022-09-15 Moshe ELKABETS Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules
CN113358872B (en) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Marker panel and system for evaluating the efficacy of tumor immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300676A1 (en) * 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
EP3428191B1 (en) * 2004-10-06 2024-12-18 Mayo Foundation for Medical Education and Research B7-h1 and pd-1 in treatment of renal cell carcinoma
WO2007136026A1 (en) * 2006-05-19 2007-11-29 Bml, Inc. Method of quantitative determination of antigen protein and quantitative determination kit therefor
EP2850102A1 (en) * 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AR095363A1 (en) 2013-03-15 2015-10-14 Genentech Inc BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1
KR102276644B1 (en) * 2013-09-04 2021-07-13 브리스톨-마이어스 스큅 컴퍼니 Compounds useful as immunomodulators
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
EP3060919A4 (en) * 2013-10-25 2018-02-14 Nodality, Inc. Methods and compositions for immunomodulation
JP6355154B2 (en) * 2014-04-03 2018-07-11 公益財団法人ヒューマンサイエンス振興財団 Diagnosis assistance method
CN107001478B (en) * 2014-10-14 2022-01-11 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
US20170242016A1 (en) 2014-10-15 2017-08-24 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1
CN108026533B (en) * 2015-09-01 2021-08-17 中央研究院 Antagonistic PDL1 aptamer and its application in cancer therapy
HUE048265T2 (en) 2015-10-27 2020-08-28 Pharmassist Ltd Method for quantification of PD-L1
BR112019004470A2 (en) 2016-09-06 2019-09-03 Incelldx Inc methods for detecting pd-l1 expression by cells and its uses

Also Published As

Publication number Publication date
MX2019002578A (en) 2019-09-18
IL265175A (en) 2019-05-30
CN112088309A (en) 2020-12-15
CR20190172A (en) 2019-06-13
CN109906367A (en) 2019-06-18
CA3036278A1 (en) 2018-03-15
BR112019004470A2 (en) 2019-09-03
WO2018048936A1 (en) 2018-03-15
US10782298B2 (en) 2020-09-22
US20180136214A1 (en) 2018-05-17
EP3510378A1 (en) 2019-07-17
WO2019136082A1 (en) 2019-07-11
JP2019535001A (en) 2019-12-05
JP2022133307A (en) 2022-09-13
EP3510378A4 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
SG11201901991QA (en) 2019-04-29 Methods of detecting per cell pd-l1 expression and uses thereof
SG11201908719QA (en) 2019-10-30 Biomarkers and car t cell therapies with enhanced efficacy
SG11201901834WA (en) 2019-03-28 Micrornas as biomarkers for endometriosis
SG11201811740WA (en) 2019-09-27 Systems and methods for identifying risky driving behavior
SG11201810221YA (en) 2018-12-28 Fidelity estimation for quantum computing systems
SG11201910019PA (en) 2019-11-28 Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201810611YA (en) 2018-12-28 Coumarin compounds and their uses as fluorescent labels
SG11201908787WA (en) 2019-10-30 Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201808022WA (en) 2018-10-30 Selection and cloning of t lymphocytes in a microfluidic device
SG11201808196UA (en) 2018-10-30 Neoantigens and methods of their use
SG11201803983UA (en) 2018-06-28 Transformable tagging compositions, methods, and processes incorporating same
SG11201810633WA (en) 2018-12-28 New fluorescent dyes and their uses as biomarkers
SG11201810887UA (en) 2019-01-30 Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201901577SA (en) 2019-05-30 Method and system for fast tracking navigation of blockchains via data manipulation
SG11201809913PA (en) 2018-12-28 Methods for detecting target nucleic acids in a sample
SG11201900772YA (en) 2019-02-27 Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201903771XA (en) 2019-05-30 Binding molecules specific for asct2 and uses thereof
SG11201804144UA (en) 2018-06-28 High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures
SG11201908743SA (en) 2019-10-30 Methods and compositions for modulation of immune cells
SG11201804360XA (en) 2018-06-28 Mat2a inhibitors for treating mtap null cancer
SG11201811550XA (en) 2019-02-27 Demand prediction for time-expiring inventory
SG11201806284TA (en) 2018-08-30 Low pressure separator having an internal divider and uses therefor
SG11201811329UA (en) 2019-01-30 Spheroids including biologically-relevant materials and related methods
SG11201907764PA (en) 2019-09-27 Methods for screening infections
SG11201805170XA (en) 2018-07-30 Cellular glycosaminoglycan compositions and methods of making and using